Total investments could reach €70 million, of which approximately 15% in R&D and 85% in capex, that would be deployed from 2026
Nous-209 has been developed using the Nouscom's viral vector platform
The company expects the GMP approval from Saudi Food and Drug Authority (SFDA) to soon pave the way for marketing authorizations from the largest market in the GCC region
New manufacturing facility dedicated to the production of active pharmaceutical ingredients (APIs) and high potency active pharmaceutical ingredients (HPAPIs)
The AGE1.CR.pIX cell line is derived from primary cells of a duck embryo and was designed to comply with health authority guidelines
Lumpi-ProVacind is used for the prophylactic immunization of animals against Lumpy Skin Disease, which illicit protection for about one year
QS-21 in blockbuster Shingles vaccine, first vaccine approved for Malaria, promising RSV phase III candidate, and Covid-19 applications.
The plant is a dedicated for manufacturing of Mouth dissolving strip.
Both the plants have a total Capex of Rs. 75 crore and expected production timeline is Q3 FY23
Company will invest approximately ¥16 billion to increase production capacity by approximately 70% to ensure a stable supply
Subscribe To Our Newsletter & Stay Updated
